linkedin

Press Releases

Samsung BIO Insight

A Strategic Roadmap for Sustainable Growth - Samsung Biologics at J.P. Morgan Healthcare Conference 2022


A Strategic Roadmap for Sustainable Growth

- Samsung Biologics at J.P. Morgan Healthcare Conference 2022

 

 

 

At the 40th Annual J.P. Morgan Healthcare Conference, which was held virtually from January 10th to 13th, Samsung Biologics’ CEO John Rim shared the company’s sustainable growth plan, consolidating its vision and business goals for 2022. 

 

During the main track presentation, which Samsung Biologics was invited to in 6 consecutive years, Rim addressed the three core pillars for the company’s multidimensional growth plan, encompassing expanded manufacturing capacity, continued advancements in business portfolio, and greater global footprint.

 

With the company aims to evolve as the top biopharmaceutical company, Rim outlined the key growth drivers for 2022 and here are some of the key highlights from the presentation. 

 

 

Key achievements of 2021

 

1.%202021%20??(ENG)_final.jpg

*Multi-Modal Plant 

*Korea Corporate Governance Service

*Dow Jones Sustainability ‘World’ Index

*Sustainable Market Initiative

 


Business goals and vision for 2022

 

1) Expanded manufacturing capacity


2.%20Capacity%20Up_??(ENG).jpg

  Plant 4 partially operational (Q4 2022) 

 Secure additional sites within Songdo for Bio Campus II

 

 

2) Advancements in business portfolio


3.%20Portfolio%20Up.jpg

  Successfully process mRNA DS cGMP Ready (Q2 2022)

 Groundbreaking of Plant 5, which will offer multi-modal products including cell & gene therapies  

and next-gen vaccines utilizing mRNA, pDNA and viral vectors, all at a single site  

 Establish plans for Open Innovation Center 

 

 

3) Greater global footprint


4.%20Geography%20Up.jpg
 

 Expand overseas, additionally to San Francisco R&D Center

  

 

VNR%20???.jpg

 

 

 

Related contents

 

Press Release Samsung Biologics Shares Strategic Roadmap for Sustainable Growth at the 40th Annual JP Morgan Healthcare Conference

News BrieJP Morgan Healthcare Conference (Audio Link)

YouTube The Future of BioPharma: Plant 4

ESG Sustainability Report 2021

 

 

 

A Strategic Roadmap for Sustainable Growth

- Samsung Biologics at J.P. Morgan Healthcare Conference 2022

 

 

 

At the 40th Annual J.P. Morgan Healthcare Conference, which was held virtually from January 10th to 13th, Samsung Biologics’ CEO John Rim shared the company’s sustainable growth plan, consolidating its vision and business goals for 2022. 

 

During the main track presentation, which Samsung Biologics was invited to in 6 consecutive years, Rim addressed the three core pillars for the company’s multidimensional growth plan, encompassing expanded manufacturing capacity, continued advancements in business portfolio, and greater global footprint.

 

With the company aims to evolve as the top biopharmaceutical company, Rim outlined the key growth drivers for 2022 and here are some of the key highlights from the presentation. 

 

 

Key achievements of 2021

 

1.%202021%20??(ENG)_final.jpg

*Multi-Modal Plant 

*Korea Corporate Governance Service

*Dow Jones Sustainability ‘World’ Index

*Sustainable Market Initiative

 


Business goals and vision for 2022

 

1) Expanded manufacturing capacity


2.%20Capacity%20Up_??(ENG).jpg

  Plant 4 partially operational (Q4 2022) 

 Secure additional sites within Songdo for Bio Campus II

 

 

2) Advancements in business portfolio


3.%20Portfolio%20Up.jpg

  Successfully process mRNA DS cGMP Ready (Q2 2022)

 Groundbreaking of Plant 5, which will offer multi-modal products including cell & gene therapies  

and next-gen vaccines utilizing mRNA, pDNA and viral vectors, all at a single site  

 Establish plans for Open Innovation Center 

 

 

3) Greater global footprint


4.%20Geography%20Up.jpg
 

 Expand overseas, additionally to San Francisco R&D Center

  

 

VNR%20???.jpg

 

 

 

Related contents

 

Press Release Samsung Biologics Shares Strategic Roadmap for Sustainable Growth at the 40th Annual JP Morgan Healthcare Conference

News BrieJP Morgan Healthcare Conference (Audio Link)

YouTube The Future of BioPharma: Plant 4

ESG Sustainability Report 2021

 

 

SITE MAP

close
Close

Thank you for Subscribing to Our Newsletter

아래 다운로드 버튼을 클릭하시면 바로 다운로드 하실 수 있습니다.

Close

Subscribe to Our Newsletter

파일 다운로드를 위해 뉴스레터 구독용 이메일 주소를 입력해주세요.
* 구독자라면 구독중인 이메일 주소를 입력해주세요.

뉴스레터 구독 서비스 유무 확인
Close

Subscribe to Our Newsletter

뉴스레터 구독 서비스를 등록하시면 당사 뉴스룸에서 제공되는
삼성바이오로직스의 최신 소식과 관심 분야별 유용한 정보를 받아 보실 수 있습니다.

Subscribe to Our Newsletter
    • - 개인정보 수집 목적 : 이메일 발신서비스 제공
    • - 개인정보 수집 항목 : 이메일 주소, 회사명, 이름, 직급, 국가
    • - 이용 및 보관 기간 : 이메일 발신서비스 해지 시까지

    개인정보 수집에 동의하지 않을 시, 뉴스레터 서비스를 이용할 수 없습니다.

    삼성바이오로직스 개인정보 보호정책에 따라 개인정보는 안전하게 관리됩니다.

close

SECURITY REPORT

Your valuable comments contribute to protecting Samsung Biologic’s core technology and management information, as well as reinforcing domestic competency and economic development.

  • This page is created for reporting core technology and management information leakage.
  • The reported contents as well as the identity of the reporter are strictly secured.
THE MANUAL FOR SECURITY NOTIFICATION

Copyright Samsung Biologics. All rights reserved